Patent · US Active

Combination therapy with an anti-axl antibody-drug conjugate

US10544223B2 · kind B2 · utility

4Cited by

92References

21Claims

0Family size

Assignees

ADC THERAPEUTICS SA · CH
MedImmune Limited · US

Inventors

Patricius Hendrikus Cornelis Van Berkel · Épalinges, CH
Jens Wuerthner · Steinen, DE
John Hartley · London, GB
Francesca ZAMMARCHI · Épalinges, CH

Key dates

Filing date	Nov 21, 2018
Grant date	Jan 28, 2020
Priority date	—
Expiry date	Nov 21, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.